Fulltext

Tackling cardiometabolic risk in the Asia Pacific region

Li JJ 1 , Yeo KK 2 , Tan K 3 , Ako J 4 , Krittayaphong R 5 , Tan RS 2 Show all authors , Aylward PE 6 , Lam CP 2 , Baek SH 7 , Dalal J 8 , Fong A 9 , Li YH 10 , O'Brien RC 11 , Koh SYN 2 , Scherer DJ 12 , Tada H 13 , Kang V 14 , Butters J 15 , Nicholls SJ 15

Affiliations 

  • 1 State Key Laboratory of Cardiovascular Disease, FuWai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences, Peking Union Medical College, BeiLiShi Road 167, Beijing 100037, China
  • 2 National Heart Centre Singapore and Duke-NUS Medical School, Singapore
  • 3 Department of Medicine, University of Hong Kong; Kitasato University, Sagamihara, Japan
  • 4 Kitasato University, Sagamihara, Japan
  • 5 Division of Cardiology, Department of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
  • 6 South Australian Health and Medical Research Institute and Flinders University, Adelaide, Australia
  • 7 Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, South Korea
  • 8 Kokilaben Hospital, Mumbai, India
  • 9 Department of Cardiology, Sarawak Heart Centre; and Clinical Research Centre, Sarawak General Hospital, Kuching, Malaysia
  • 10 National Cheng Kung University Hospital, Tainan, Taiwan
  • 11 University of Melbourne and Austin Health, Melbourne, Australia
  • 12 South Australian Health and Medical Research Institute, Australia
  • 13 Kanazawa University Graduate School of Medicine, Kanazawa, Japan
  • 14 Singapore Heart Foundation, Singapore
  • 15 Monash Cardiovascular Research Centre, Victorian Heart Institute, Monash University, Melbourne, Australia
Am J Prev Cardiol, 2020 Dec;4:100096.
PMID: 34327472 DOI: 10.1016/j.ajpc.2020.100096

Abstract

With the global spread of abdominal obesity, cardiovascular disease continues to spread to all countries of the world. Given the large population, the challenges presented by cardiometabolic risk in the Asia Pacific region are considerable. In addition to the clinical consequences of cardiovascular disease, in terms of its morbidity and mortality, the diversity of the Asia Pacific region brings heterogeneity in approaches to prevention, diagnosis and treatment of cardiometabolic risk. In this manuscript, we will review the current state of knowledge of cardiometabolic risk in Asia Pacific and highlight the needs moving forward to tackle this public health challenge.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications